136 related articles for article (PubMed ID: 27048112)
1. Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.
Nieuwenhuyzen-de Boer GM; Gerestein CG; Eijkemans MJ; Burger CW; Kooi GS
Eur J Gynaecol Oncol; 2016; 37(1):63-8. PubMed ID: 27048112
[TBL] [Abstract][Full Text] [Related]
2. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.
Gerestein CG; Nieuwenhuyzen-de Boer GM; Eijkemans MJ; Kooi GS; Burger CW
Eur J Cancer; 2010 Jan; 46(1):102-9. PubMed ID: 19900801
[TBL] [Abstract][Full Text] [Related]
3. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
[TBL] [Abstract][Full Text] [Related]
4. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
[TBL] [Abstract][Full Text] [Related]
5. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
[TBL] [Abstract][Full Text] [Related]
6. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
8. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.
Gerestein CG; Eijkemans MJ; de Jong D; van der Burg ME; Dykgraaf RH; Kooi GS; Baalbergen A; Burger CW; Ansink AC
BJOG; 2009 Feb; 116(3):372-80. PubMed ID: 19187369
[TBL] [Abstract][Full Text] [Related]
9. Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer: A Single-center Experience.
Bacalbasa N; Dima S; Balescu I; David L; Brasoveanu V; Popescu I
Anticancer Res; 2015 Jul; 35(7):4099-104. PubMed ID: 26124361
[TBL] [Abstract][Full Text] [Related]
10. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.
Fotopoulou C; Jones BP; Savvatis K; Campbell J; Kyrgiou M; Farthing A; Brett S; Roux R; Hall M; Rustin G; Gabra H; Jiao L; Stümpfle R
Arch Gynecol Obstet; 2016 Sep; 294(3):607-14. PubMed ID: 27040418
[TBL] [Abstract][Full Text] [Related]
11. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.
Xu XL; Cheng H; Tang MS; Zhang HL; Wu RY; Yu Y; Li X; Wang XM; Mai J; Yang CL; Jiao L; Li ZL; Zhong ZM; Deng R; Li JD; Zhu XF
Oncotarget; 2017 Jan; 8(5):8120-8130. PubMed ID: 28042955
[TBL] [Abstract][Full Text] [Related]
12. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
13. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
Kumar A; Janco JM; Mariani A; Bakkum-Gamez JN; Langstraat CL; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Jan; 140(1):15-21. PubMed ID: 26541980
[TBL] [Abstract][Full Text] [Related]
14. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
[TBL] [Abstract][Full Text] [Related]
17. Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer.
Xiang L; Tu Y; He T; Shen X; Li Z; Wu X; Yang H
J Gynecol Oncol; 2016 Nov; 27(6):e62. PubMed ID: 27550408
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
19. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
20. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.
Chi DS; Palayekar MJ; Sonoda Y; Abu-Rustum NR; Awtrey CS; Huh J; Eisenhauer EL; Barakat RR; Kattan MW
Gynecol Oncol; 2008 Jan; 108(1):191-4. PubMed ID: 17950784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
